FA
THRX

Forefront Analytics’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Forefront Analytics’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,672
Closed -$47.5K – 70
2023
Q3 		$47.5K Buy
+17,672
New +$69.3K 0.03% 66
2022
Q4 		– Sell
-13,065
Closed -$74K – 80
2022
Q3 		$74K Buy
+13,065
New +$92.3K 0.04% 55

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Forefront Analytics's THRX Position: Q4 2023 in Review

Forefront Analytics sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2023, closing a stake of 17,672 shares — an estimated $47.5K sold.

Forefront Analytics first reported a position in THRX in Q3 2022 and held it in 2 quarters. The position peaked at $74K in Q3 2022. 70 funds tracked by Wall St. Rank hold THRX as of Q4 2023.

  • Forefront Analytics reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Forefront Analytics sold 17,672 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $47.5K.
  • Forefront Analytics first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Forefront Analytics's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $74K in Q3 2022.
  • 70 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Forefront Analytics's 13F filing for Q4 2023, filed 14 Feb 2024.